An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

ZYDELIG®

Drug Information Related Patent
Hold Company
GILEAD SCIENCES INC
Learn More
Dosage and Administration
TABLET;ORAL
Specification
100MG; 150MG
Indication
ZYDELIG® is suitable for recurrent chronic lymphocytic leukemia, recurrence of follicular B cell non-hodgkin's lymphoma and recurrence small lymphocytic lymphoma.
Use
Instructions for Use
API
IDELALISIB
API Structure
We Supply
IDELALISIB
Note:

Facility GMP
USMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
107308792033/3/5
88657302033/3/5
89809012025/5/12
91494772025/5/12
94696432033/9/2
94924492030/3/11
RE445992025/7/21
RE446382025/8/5
API Patent
Patent NoExpiration Date
89809012025/5/12
91494772025/5/12
RE445992025/7/21
RE446382025/8/5
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top